REG - IQ-AI Limited - Issue of shares to Mayo Clinic

IQ-AIAnnouncement

08/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220208:nRSH9343Aa&default-theme=true

RNS Number : 9343A  IQ-AI Limited  08 February 2022

8 February 2022

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Issue of shares to Mayo Clinic

 

Further to the Company's announcement dated 9 November 2020, IQ-AI announces
the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the "New
Ordinary Shares") to Mayo Clinic, at a price of 6.41p per share. The New
Ordinary Shares were issued in accordance with the research and collaboration
agreement regarding IB Trax, entered into between Mayo Clinic and Imaging
Biometrics, LLC, a subsidiary of IQ-AI.

 

Application will be made for the 113,781 New Ordinary Shares to be admitted to
the Official List of the UK Listing Authority by way of a Standard Listing
("Admission") and it is expected that Admission will become effective and that
dealing in the New Ordinary Shares will commence on or around 8 am on 11
February 2022. The New Ordinary Shares will rank pari passu with the existing
ordinary shares of the Company.

 

Following Admission, the Company will have 182,621,390 ordinary shares of 1p
each in issue, none of which are held in treasury. Therefore, the total number
of voting rights in the Company is 182,621,390.

 

The above figure of 182,621,390 may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure and Transparency
Rules.

 

The Directors of the Company accept responsibility for the contents of this
announcement

 

-ENDS-

 

For further information, please contact:

 IQ-AI Limited

 Trevor Brown/Brett Skelly/Vinod Kaushal

 Tel: 020 7469 0930

 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law
(as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESSEFIWEESEDE